ES2552989T3 - Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina - Google Patents

Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina Download PDF

Info

Publication number
ES2552989T3
ES2552989T3 ES12769775.3T ES12769775T ES2552989T3 ES 2552989 T3 ES2552989 T3 ES 2552989T3 ES 12769775 T ES12769775 T ES 12769775T ES 2552989 T3 ES2552989 T3 ES 2552989T3
Authority
ES
Spain
Prior art keywords
alkyl
group
heterocyclyl
halogen
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12769775.3T
Other languages
English (en)
Inventor
James F. Blake
Huifen Chen
Mark Joseph Chicarelli
Jason Demeese
Rustam Ferdinand GARREY
John Gaudino
Lewis Gazzard
Robert J. Kaus
Samuel Kintz
Peter J. Mohr
David A. Moreno
Jacob Schwarz
Christopher S. SIEDEM
Eli M. Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2552989T3 publication Critical patent/ES2552989T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de acuerdo con la fórmula I**Fórmula** en la que: R1 es heterociclilo o heteroarilo seleccionado de entre el grupo que consiste en pirazolilo, triazolilo oxadiazolilo, oxazolilo, imidazolilo, isoxazolilo, pirrolidinilo, piperidinilo o morfolinilo opcionalmente sustituidos con entre uno y tres sustituyentes seleccionados independientemente de entre el grupo que consiste en alquilo C1-6, hidroxialquilo C1-6, halógeno, hidroxilo y oxo; Ar es fenilo o piridinilo opcionalmente sustituidos con entre 1 y 5 grupos seleccionados independientemente de entre el grupo que consiste en alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, cicloalquilo C1-6, halógeno, haloalcoxi C1-6, alquiltio C1-6, acilamino C1-6, ciano y nitro; R2 se selecciona de entre el grupo que consiste en (a) alquilo C1-10, (b) haloalquilo C1-6, (c) heterociclilo o heterociclil-alquilo C1-6 en donde dichos heterociclo o heterociclil-alquilo C1-6 se seleccionan de entre el grupo que consiste en tetrahidropiranilo, tetrahidrofuranilo, 2-oxabiciclo[2.2.1]heptan-5-ilo, oxetanilo, piperidinilo, N-alquilo C1-6-piperidinilo, 1,1-dioxotietan-3-ilo, tietan-3-ilo y N-alquilo C1-6-2-oxo-pirrolidinilo, y en donde dichos heterociclilo o heterociclil-alquilo C1-6 están opcionalmente sustituido con entre 1 y 3 grupos seleccionados independientemente de entre el grupo que consiste en alquilo C1-6, haloalquilo C1-6, aciloxi C1-4-alquilo C1-2, halógeno, hidroxilo, fenilo, hidroxialquilo C1-3 y oxo, (d) cicloalquilo C3-7 o cicloalquilo C3-7-alquilo C1-6 en donde dichos cicloalquilo o cicloalquilo C3-7-alquilo C1-6 están opcionalmente sustituidos con entre uno y tres grupos hidroxilo, alcoxi C1-3 o halo, (e) heteroalquilo C1-6 en donde la fracción heteroalquilo incluye al menos hidroxialquilo C1-6 o alcoxi C1-3-alcoxi C1-6, (f) heteroarilo en donde dicho heteroarilo se selecciona de entre el grupo que consiste en pirazolilo y piridinilo en donde dicho heteroarilo está opcionalmente independientemente sustituido con entre uno y tres grupos seleccionados de entre el grupo que consiste en grupos alquilo C1-6, haloalquilo C1-6 y halógeno, y (g) cianoalquilo C1-3; R3 es hidrógeno o halógeno; o, un estereoisómero, un tautómero o una sal farmacéuticamente aceptables de los mismos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
nomenclatura convencional que incluye los prefijos normal (n-), iso (i-), secundario (sec-), terciario (terc-) y neo-tiene su significado habitual cuando se usa con una fracción alquilo (J. Rigaudy y D. P. Klesney, Nomenclature in Organic Chemistry, IUPAC 1979 Pergamon Press, Oxford.).
5 COMPUESTOS Y PREPARACIÓN
Algunos ejemplos de los compuestos representativos en el ámbito de la invención se proporcionan en la siguiente Tabla. Estos ejemplos y las preparaciones que siguen se proporcionan para permitir que los expertos en la materia comprendan con más claridad y lleven a la práctica la presente invención. No deberían ser considerados como
10 limitantes del ámbito de la invención, sino simplemente como ilustrativos y representativos de la misma.
Si hubiera una discrepancia entre una estructura representada y un nombre proporcionado a esa estructura, se acuerda que la estructura representada debe tener más peso. Además, si la estereoquímica de una estructura o de una porción de una estructura no está indicada, por ejemplo, con unas líneas en negrita o discontinuas, debe
15 interpretarse que la estructura o la porción de la estructura engloba todos los estereoisómeros de la misma. En el presente documento se usa el siguiente sistema de numeración.
imagen19
TABLA I
Comp. Nº
Estructura CI501 (µM) EM2 RMN-1H
I -1
0,0025 469,2 (CDCl3) δ 9,02 (s, 1H), 7,82 (s, 1H), 7,73 (m, 2H), 7,40 (m, 1H), 7,18 (m, 3H), 6,71 (m, 1H), 6,33 (d, 1H), 5,46 (m, 1H), 4,27 (m, 1H), 3,89 (s, 3H), 3,85 (m, 1H), 3,72 (m, 1H), 1,34 (d, 3H), 1,25 (m, 1H)
I -2
0,0008 495,0 (CDCl3) δ 9,02 (s, 1H), 7,85 (s, 1H), 7,75 (d, 1H), 7,67 (d, 1H), 7,40 (t, 2H), 7,20 (m, 2H), 7,15 (d, 1H), 6,70 (d, 1H), 6,33 (d, 1H), 5,30 (m, 1H), 4,20 (m, 1H), 4,03 (m, 2H), 3,89 (s, 3H), 3,60 (t, 2H), 2,12 (d, 2H), 1,62 (m, 2H)
I -3
imagen20 0,0021 518,2 (CDCl3) δ 9,02 (s, 1H), 7,97 (s, 1H), 7,72 (m, 2H), 7,58 (m, 1H), 7,23 (m, 2H), 5,35 (d, 1H), 5,15 (dd, 1H), 4,26 (m, 1H), 4,04 (m, 2H), 3,62 (m, 2H), 3,55 (m a,, 1H), 3,05 (m, 1H), 2,94 (m, 1H), 2,14 (m, 2H), 2,02 (m, 1H), 1,74 (m, 6H)
I -4
0,0050 495,0 (CDCl3) δ 9,01 (s, 1H), 7,96 (s, 1H), 7,72 (dd, 2H), 7,65 (d, 1H), 7,34 (m, 2H), 7,22 (m, 2H), 6,28 (d, 1H), 6,07 (d, 1H), 5,26 (d, 1H), 4,24 (m, 1H), 4,03 (m, 2H), 3,92 (s, 3H), 3,61 (m, 2H), 2,12 (d, 2H), 1,62 (m, 2H)
I -5
0,0023 476,0
I -6
imagen21 0,0050 469,0
I -7
0,0018 518,1 (CDCl3) δ 9,01 (s, 1H), 7,89 (s, 1H), 7,73 (d, 1H), 7,66 (dd, 1H), 7,57 (m, 1H), 7,32 (s a, 1H), 7,29 (d, 1H), 7,18 (d, 1H), 5,30 (d, 1H), 5,05 (m, 1H), 4,24 (m, 1H), 4,04 (m, 2H), 3,62 (m, 3H), 2,90 (m, 2H), 2,14 (d, 2H), 1,86 (m, 1H), 1,62 (m, 6H)
I -8
0,0067 485,2
I -9
0,0067 485,2
I -10
0,0054 485,1
I -11
0,0064 485,1 (CDCl3) δ 8,94 (s, 1H), 7,87 (s, 1H), 7,60 (m, 2H), 7,53 (d, 1H), 7,32 (m, 1H), 7,07 (m, 1H), 5,41 (s a, 1H), 5,19 (m, 1H), 4,17 (s a, 1H), 4,00 (d, 2H), 3,56 (m, 2H), 3,44 (s a, 1H), 3,32 (m, 1H), 3,17 (m, 1H), 3,05 (m, 1H), 2,95 (m, 1H), 2,27 (m, 1H), 2,06 (m, 3H), 1,60 (m, 3H)
I -12
imagen22 0,0014 495,1 (CDCl3) δ 9,01 (s, 1H), 7,85 (s, 1H), 7,71 (dd, 2H), 7,40 (m, 2H), 7,19 (m, 2H), 7,15 (d, 1H), 6,72 (d, 1H), 6,33 (d, 1H), 5,30 (d, 1H), 4,20 (m, 1H), 4,02 (m, 2H), 3,89 (s, 3H), 3,59 (m, 2H), 2,12 (d, 2H), 1,61 (m, 2H)
I -13
0,0388 495,1 (CDCl3) δ 9,01 (s, 1H), 7,85 (s, 1H), 7,71 (dd, 2H), 7,40 (m, 2H), 7,19 (m, 2H), 7,15 (d, 1H), 6,72 (d, 1H), 6,33 (d, 1H), 5,30 (d, 1H), 4,20 (m, 1H), 4,02 (m, 2H), 3,89 (s, 3H), 3,59 (m, 2H), 2,12 (d, 2H), 1,61 (m, 2H)
I -14
0,0568 469,2
I -15
0,0012 469,2
I -16
503,1
I -17
0,0028 532,1 (CDCl3) δ 9,04 (s, 1H), 7,96 (s, 1H), 7,73 (dd, 2H), 7,56 (m, 1H), 7,20 (d, 1H),7,15 (d, 1H), 5,30 (d, 1H), 5,07 (m, 1H), 4,26 (m, 1H), 4,04 (m, 2H), 3,62 (m, 2H), 3,19 (m, 1H), 2,59 (m, 1H), 2,36 (s, 3H), 2,34 (m, 1H), 2,14 (d, 2H), 1,78 (m, 1H), 1,65 (m, 2H), 1,40 (m, 1H)
I -18
0,0128 509,0 (CDCl3) δ 9,02 (s, 1H), 7,86 (s, 1H), 7,72 (dd, 2H), 7,41 (m, 2H), 7,21 (s, 1H), 7,18 (m, 2H), 6,72 (d, 1H), 6,33 (d, 1H), 5,30 (d, 1H), 4,20 (m, 1H), 4,15 (c, 2H), 4,02 (m, 2H), 3,60 (m, 2H), 2,12 (d, 2H), 1,62 (m, 2H), 1,49 (t, 3H)
I -19
0,0024 509,1 (CDCl3) δ 9,02 (s, 1H), 7,86 (s, 1H), 7,72 (dd, 2H), 7,41 (m, 2H), 7,21 (s, 1H), 7,18 (m, 2H), 6,72 (d, 1H), 6,33 (d, 1H), 5,30 (d, 1H), 4,20 (m, 1H), 4,15 (c, 2H), 4,02 (m, 2H), 3,60 (m, 2H), 2,12 (d, 2H), 1,62 (m, 2H), 1,49 (t, 3H)
I -20
0,0020 495,0
I -21
0,069 495,0
I -22
0,0014 513,0 (CDCl3) δ 9,26 (s, 1H), 7,62 (s, 1H), 7,38 -7,43 (m, 2H), 7,29 7,34 (m, 1H), 7,19 (m, 1H), 7,15 (m, 1H), 6,67 (m, 1H), 6,31 (m, 1H), 5,40 (m, 1H), 4,20 (s, 1H), 4,00 -4,06 (m, 2H), 3,89 (s, 3H), 3,59 (m, 2H), 2,11 (m, 2H), 1,59 -1,68 (m, 2H)
I -23
imagen23 0,0023 484,0 (CDCl3) δ 9,01 (s, 1H), 7,88 (s, 1H), 7,70 (dd, 2H), 7,36 (m, 1H), 7,21 (dd, 2H), 7,12 (d, 1H), 5,29 (d, 1H), 5,01 (m, 1H), 4,24 (m, 1H), 4,04 (m, 2H), 3,60 (m, 2H), 3,56 (m, 1H), 2,87 (m, 2H), 2,13 (d, 2H), 1,87 (m, 1H), 1,60 (m, 4H)
I -24
0,0082 480
I -25
imagen24 0,0090 498,0 (d6-DMSO) δ 9,29 (s, 1H), 9,03 (m, 1H), 7,87 (m, 1H), 7,30 (m, 2H), 7,18 (m, 1H), 7,09 (m, 1H), 4,75 (m, 1H), 4,10 (m, 1H), 3,91 (m, 2H), 3,81 (s, 3H), 3,74 (s, 1H), 3,39 -3,49 (m, 4H), 2,71 -2,83 (m, 2H), 1,89 (m, 4H), 1,52 -1,71 (m, 4H)
I -26
0,002 464 (d6-DMSO) δ 9,13 (s, 1H), 8,97 (d, 1H), 7,90 (s, 1H), 7,82 (d, 1H), 7,54 (m, 1H), 7,48 (s a, 1H), 7,32 (m, 1H), 7,20 (m, 1H), 7,10 (m, 1H), 5,76 (m, 1H), 4,82 (m, 1H), 3,80 (s, 3H), 3,67 (m, 1H), 3,50 (m, 1H), 2,81 (m, 2H), 1,92 (m, 1H), 1,67 (m, 2H), 1,51 (m, 1H), 1,25 (d, 3H), 1,02 (m, 1H), 0,45 (m, 1H), 0,36 (m, 2H), 0,20 (m, 1H)
I -27
0,0158 513
I -28
0,0025 513 (d6-DMSO) δ 9,44 (d, 1H), 9,22 (s, 1H), 8,04 (s a, 1H), 7,90 (d, 1H), 7,67 (d, 1H), 7,58 (m, 2H), 7,49 (d, 1H), 7,38 (s, 1H), 7,32 (d, 1H), 6,32 (d, 1H), 4,88 (d a, 1H), 4,26 (d a, 1H), 4,03 (m, 1H), 3,93 (d, 1H), 3,79 (s, 3H), 3,56 (m, 2H), 2,00 (m, 1H), 1,70 (d, 1H)
I -29
imagen25 0,0038 513 (d6-DMSO) δ 9,46 (d, 1H), 9,22 (s, 1H), 8,06 (s a, 1H), 7,88 (d, 1H), 7,82 (s a, 1H), 7,66 (d, 1H), 7,58 (m, 1H), 7,58 (s, 1H), 7,49 (d, 1H), 7,38 (s, 1H), 7,32 (d, 1H), 6,33 (d, 1H), 4,61 (d a, 1H), 4,38 (s a, 1H), 4,04 (m, 1H), 3,86 (d, 1H), 3,80 (s, 3H), 3,50 (m, 2H), 2,06 (m, 1H), 1,65 (d, 1H)
I -30
0,0021 513 (d6-DMSO) δ 9,46 (d, 1H), 9,22 (s, 1H), 8,07 (s a, 1H), 7,88 (d, 1H), 7,66 (m, 1H), 7,58 (m, 2H), 7,49 (m, 1H), 7,38 (s, 1H), 7,32 (d, 1H), 6,32 (d, 1H), 4,61 (d a, 1H), 4,38 (s a, 1H), 4,04 (m, 1H), 3,86 (m, 1H), 3,80 (s, 3H), 3,45 (m, 2H), 2,06 (d a, 1H), 1,65 (m, 1 H)
I -31
0,0017 498,5 (CDCl3) δ 9,01 (s, 1H), 7,94 (s, 1H), 7,70 (m, 2H), 7,11 (m, 1H), 7,09 (m, 2H), 6,95 (m, 1H), 5,25 (m, 2H), 5,22 (m, 1H), 4,23 (m, 1H), 4,03 (m, 2H), 3,88 (s, 3H), 3,68 (m,, 1H), 3,61 (m, 2H), 3,39 (m, 1H), 2,93 (m, 1H), 2,13 (d, 2H), 2,00 (m, 1H), 1,62 (m, 2H)
I -32
0,0011 491 (d6-DMSO) δ 9,37 (d, 1H), 9,17 (s, 1H), 8,02 (s, 1H), 7,84 (m, 1H), 7,62 (m, 1H), 7,54 (m, 2H), 7,30 (m, 2H), 7,16 (m, 2H), 6,26 (m, 1H), 5,75 (m, 1H), 4,08 (s a, 1H), 3,90, (m, 2H), 3,82 (s, 3H), 3,79 (s, 3H), 3,42 (m, 2H), 1,90 (m, 2H), 1,58 (m, 2H),
I -33
imagen26 0,0015 509 (d6-DMSO) δ 9,41 (d, 1H), 9,30 (s, 1H), 7,93 -7,85 (m, 2H), 7,54 (s, 1H), 7,38 -7,25 (m, 3H), 7,22 -7,11 (m, 2H), 6,25 (d, 1H), 4,15 -4,05 (m, 1H), 3,93 -3,85 (m, 2H), 3,72 (s, 3H), 3,69 (s, 3H), 3,47 -3,38 (m, 2H), 1,93 -1,85 (m, 2H), 1,64 -1,53 (m, 2H)
I -34
0,0036 482,7 (d6-DMSO) δ 9,99 (d, 1H), 9,20 (s, 1H), 9,04 (s, 1H), 8,06 (s, 1H), 7,89 (d, 1H), 7,67 (m, 4H), 7,45 (d, 1H), 6,79 (d, 1H), 4,07 (s a, 1H), 3,90 (d, 2H), 3,42 (m, 2H), 1,89 (d, 2H), 1,57 (m, 2H)
I -35
imagen27 0,0020 498,0 (CDCl3) δ 9,01 (s, 1H), 7,88 (s, 1H), 7,69 (m, 2H), 7,37 (m, 1H), 7,16 (d, 1H), 7,01 (d, 1H), 5,28 (d, 1H), 5,01 (m, 1H), 4,24 (m, 1H), 4,04 (m, 2H), 3,61 (m, 2H), 3,58 (m, 1H), 3,22 (m, 1H), 2,13 (d, 2H), 1,80 (m, 2H), 1,62 (m, 2H), 1,57 (m, 4H), 1,11 (d, 3H)
I -36
0,0016 502,2
I -37
0,0736 502,1, 504,13
I -38
0,0654 502,2
I -39
0,0012 502,2
I -40
0,0073 497,0
I -41
0,00055 509,0 (CDCl3) δ 9,01 (s, 1H), 7,85 (s, 1H), 7,71 (m, 2H), 7,41 (m, 3H), 7,19 (s, 1H), 7,14 (m, 2H), 6,73 (d, 1H), 6,37 (d, 1H), 5,29 (d, 1H), 4,20 (m, 1H), 4,02 (m, 2H), 3,88 (s, 3H), 3,60 (m, 2H), 2,12 (d, 2H), 1,62 (m, 2H)
I -42
0,0072 525,2 (CDCl3) δ 9,03 (s, 1H), 7,86 (s, 1H), 7,72 (dd, 2H), 7,40 (m, 1H), 7,39 (s, 1H), 7,20 (s, 1H), 7,17 (m, 2H), 6,72 (d, 1H), 6,33 (d, 1H), 5,63 (d, 1H), 4,48 (m, 1H), 3,97 (m, 1H), 3,89 (s, 3H), 3,79 (m, 2H), 3,59 (m, 2H), 2,02 (m, 2H), 1,88 (m, 2H), 1,78 (m, 1H)
I -43
521,2 (DMSO) 9,33 (t, J = 10,4 Hz, 1H), 9,14 (d, J = 15,8 Hz, 1H), 8,01 (s, 1H), 7,89 -7,79 (m, 1H), 7,61 (t, J = 9,2 Hz, 1H), 7,56 -7,40 (m, 2H), 7,32 (d, J = 9,4 Hz, 1H), 7,26 (t, J = 11,7 Hz, 1H), 7,20 (d, J = 8,8 Hz, 1H), 7,12 (dd, J = 16,9, 8,4 Hz, 1H), 6,25 (t, J = 12,6 Hz, 1H), 4,60 (d, J = 19,4 Hz, 1H), 4,12 (d, J = 7,7 Hz, 1H), 3,95 (dd, J = 11,5, 3,8 Hz, 1H), 3,82 (s, 4H), 3,79 (s, 4H), 3,44 (dd, J =18,5, 7,7 Hz, 2H), 1,92 (dd, J = 29,5, 12,4 Hz, 2H), 1,51 (cd, J = 12,3, 4,5 Hz, 1H), 1,24 (c, J = 11,6 Hz, 1H)
I -44
0,001 507,2 (DMSO-d6) δ 9,40 (d, J = 8,5 Hz, 1H), 9,17 (s, 1H), 8,03 (s, 1H), 7,85 (d, J = 8,0 Hz, 1H), 7,63 (m, 1H), 7,58 -7,55 (m, 2H), 7,48 (d, J = 2,0 Hz, 1H), 7,38 -7,35 (m, 2H), 7,13 (d, J = 8,5 Hz, 1H), 6,27 (d, J = 8,5 Hz, 1H), 4,09 (m, 1H), 3,91 -3,89 (m, 2H), 3,84 (s, 3H), 3,80 (s, 3H), 3,44 -3,40 (m, 2H), 1,90 -1,88 (m, 2H), 1,61 1,54 (m, 2H)
I -45
0,022 502,1 (MeOH -d4) δ 9,11 (s, 1H), 8,00 (s, 1H), 7,87 -7,84 (m, 2H), 7,71 (s, 1H), 7,64 (m, 1H), 7,59 -7,56 (m, 2H), 7,45 (s, 1H), 6,44 (s, 1H), 4,19 (m, 1H), 4,03 -4,01 (m, 2H), 3,89 (s, 3H), 3,62 -3,57 (m, 2H), 2,07 2,05 (m, 2H), 1,69 -1,65 (m, 2H)
I -46
0,0042 521,2 (DMSO) 9,34 (d, J = 8,6 Hz, 1H), 9,19 (s, 1H), 8,01 (s, 1H), 7,86 (d, J = 8,3 Hz, 1H), 7,72 (d, J = 6,4 Hz, 1H), 7,64 (d, J = 8,3 Hz, 1H), 7,55 (d, J = 8,5 Hz, 1H), 7,35 -7,25 (m, 2H), 7,16 (dt, J = 17,2, 8,6 Hz, 2H), 6,27 (d, J = 8,5 Hz, 1H), 4,51 (s, 1H), 4,33 (s, 1H), 4,17 -3,94 (m, 2H), 3,82 (t, J = 11,8 Hz, 8H), 3,70 (dd, J = 16,9, 10,0 Hz, 2H), 1,83 (t, J = 14,8 Hz, 2H), 1,72 (d, J = 14,2 Hz, 1H), 1,59 -1,49 (m, 1H)
I -47
0,0014 525,5
I -48
0,0011 502,2
I -49
0,141 498,2
I -50
0,025 502,2
I -51
0,0028 510,2
I -52
imagen28 0,0026 527,2 RMN-1H (400 MHz, DMSO) δ 9,60 (d, J = 8,2 Hz, 1H), 9,30 (s, 1H), 7,89 (m, 2H), 7,63 (s, 1H), 7,33 (dd, J = 22,1, 10,8 Hz, 2H), 7,18 (dt, J = 17,2, 8,6 Hz, 2H), 6,44 (d, J = 8,4 Hz, 1H), 4,10 (m, 4H), 3,90 (d, J = 11,4 Hz, 2H), 3,82 (s, 3H), 3,42 (t, J = 11,3 Hz, 2H), 1,89 (m, 2H), 1,59 (cd, J = 12,0, 4,2 Hz, 2H)
I -53
0,0068 510,2
I -54
0,031 510,2
I -55
0,0027 495,2
I -56
0,0035 498,2
I -57
0,024 563,2 (DMSO) 9,34 (d, J = 8,6 Hz, 1H), 9,20 (s, 1H), 8,02 (s, 1H), 7,87 (d, J = 8,3 Hz, 1H), 7,78 (d, J = 6,5 Hz, 1H), 7,65 (d, J = 8,3 Hz, 1H), 7,54 (s, 1H), 7,36 -7,24 (m, 2H), 7,16 (dt, J = 17,2, 8,6 Hz, 2H), 6,26 (d, J = 8,5 Hz, 1H), 4,34 (s, 1H), 4,01 (ddd, J = 31,9, 17,1,7,3 Hz, 4H), 3,80 (d, J = 12,8 Hz, 7H), 3,73 (d, J = 11,2 Hz, 1H), 2,02 (s, 3H), 1,82 (d, J = 12,0 Hz, 2H), 1,75 (d, J = 13,5 Hz, 1H), 1,63 (dd, J = 17,0, 7,0 Hz, 1H)
I -58
0,020 483,2 (DMSO) 9,40 (d, J = 8,3 Hz, 1H), 9,29 (s, 1H), 7,91 (s, 1H), 7,82 (s, 1H), 7,54 (s, 1H), 7,36 (d, J = 10,3 Hz, 1H), 7,32 (s, 1H), 7,27 (dd, J = 12,6, 1,9 Hz, 1H), 7,21 -7,17 (m, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,57 (m, 4H), 3,28 (s, 3H)
I -59
0,015 485,2 (DMSO) 9,40 (d, J = 8,4 Hz, 1H), 9,29 (s, 1H), 7,91 (s a, 2H), 7,54 (s, 1H), 7,36 (d, J = 10,6 Hz, 1H), 7,32 (s, 1H), 7,27 (dd, J = 12,6, 1,9 Hz, 1H), 7,20 (dd, J = 8,6, 1,8 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,56 (dt, J = 47,4, 5,8 Hz, 2H), 3,82 (s, 3H), 3,79 (s, 3H), 3,49 (m, 2H), 2,10 1,87 (m, 2H)
I -60
0,006 479,2 (DMSO) 9,39 (d, J = 8,5 Hz, 1H), 9,28 (s, 1H), 7,92 (m, 2H), 7,54 (s, 1H), 7,34 (m, 2H), 7,27 (dd, J = 12,6, 1,9 Hz, 1H), 7,22 -7,17 (m, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,24 (d, J = 8,4 Hz, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,25 (m, 2H), 1,15 (m, 1H), 0,49 -0,40 (m, 2H), 0,26 (m, 2H)
I -61
0,002 495,2 (DMSO) 9,41 (d, J = 8,5 Hz, 1H), 9,31 (s, 1H), 8,09 (s, 1H), 7,91 (s, 1H), 7,54 (s, 1H), 7,38 (d, J = 10,5 Hz, 1H), 7,33 (s, 1H), 7,27 (dd, J = 12,6, 1,8 Hz, 1H), 7,22 -7,17 (m, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,51 (s, 1H), 3,94 (dd, J = 8,8, 6,1 Hz, 1H), 3,87 (dd, J = 15,2, 7,4 Hz, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,75 (m, 1H), 3,64 (m, 1H), 2,20 (m, 7,6 Hz, 1H), 1,96 (m, 1H)
I -62
0,004 495,2 (DMSO) 9,41 (d, J = 8,5 Hz, 1H), 9,31 (s, 1H), 8,09 (s, 1H), 7,91 (s, 1H), 7,54 (s, 1H), 7,38 (d, J = 10,4 Hz, 1H), 7,32 (s, 1H), 7,27 (d, J = 12,7 Hz, 1H), 7,20 (d, J = 10,0 Hz, 1H), 7,14 (t, J = 8,5 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,50 (s, 1H), 3,96 -3,90 (m, 1H), 3,86 (t, J = 7,5 Hz, 1H), 3,82 (s, 3H), 3,79 (s, 3 H), 3,75 (m, 1H), 3,67 -3,59 (m, 1H), 2,20 (m, 1H), 1,97 (m, 1H)
I -63
0,004 495,2 (DMSO) 9,40 (d, J = 8,5 Hz, 1H), 9,29 (s, 1H), 8,02 (s, 1H), 7,92 (s, 1H), 7,54 (s, 1H), 7,37 (d, J = 10,4 Hz, 1H), 7,32 (s, 1H), 7,27 (dd, J = 12,6, 1,7 Hz, 1H), 7,20 (d, J = 8,6 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,70 -4,62 (m, 2H), 4,37 (t, J = 5,9 Hz, 2H), 3,82 (s, 3H), 3,79 (s, 3H), 3,68 (t, J = 6,2 Hz, 2H), 3,26 (m, 1H)
I -64
0,006 495,2 (DMSO) 9,41 (d, J = 8,4 Hz, 1H), 9,33 (s, 1H), 8,30 (s, 1H), 7,81 (s, 1H), 7,53 (s, 1H), 7,41 (d, J = 10,4 Hz, 1H), 7,32 (s, 1H), 7,27 (dd, J = 12,6, 1,8 Hz, 1H), 7,21 -7,17 (m, 1H), 7,14 (t, J = 8,5 Hz, 1H), 6,24 (d, J = 8,4 Hz, 1H), 4,74 (d, J = 6,2 Hz, 2H), 4,46 (d, J = 6,2 Hz, 2H), 3,82 (s, 3H), 3,79 (s, 3H), 1,69 (s, 3H)
I -65
imagen29 0,0006 520,2
I -66
0,0006 525,2
I -67
0,005 521,2 (DMSO-d6) δ 9,10 (s, 1H), 7,97 (s, 1H), 7,86 (d, J = 9,0 Hz, 1H), 7,64 (d, J = 8,5 Hz, 1H), 7,56 (s, 1H), 7,44 (s, 1H), 7,22 (m, 2H), 7,13 (m, 1H), 6,36 (s, 1H), 4,22 (m, 3H), 4,03 (m, 2H), 3,89 (m, 5H), 3,61 (m, 2H), 2,07 (m, 2H), 1,68 (m, 2H)
I -68
0,0013 479,2 RMN-1H (400 MHz, DMSO) δ 9,46 (d, J = 8,4 Hz, 1H), 9,30 (s, 1H), 7,92 (s, 1H), 7,84 (s, 1H), 7,56 (s, 1H), 7,44 -7,33 (m, 3H), 7,30 -7,23 (m, 2H), 7,10 (td, J = 8,8, 2,4 Hz, 1H), 6,32 (d, J = 8,3 Hz, 1H), 4,10 (s a, 1 H), 3,90 (d, J = 11,1 Hz, 2H), 3,79 (s, 3 H), 3,42 (t, J = 11,1 Hz, 2H), 1,89 (d, J = 11,5 Hz, 2H), 1,59 (cd, J = 11,4, 4 Hz, 2H)
I -69
0,0012 523,2 RMN-1H (400 MHz, DMSO) δ 9,40 (d, J = 8,0 Hz, 1H), 9,25 (s, 1H), 7,91 (s, 1H), 7,68 (d a, J = 6,8 Hz, 1H), 7,54 (s, 1H), 7,33 (d, J = 9,6 Hz, 1H), 7,32 (s, 1H), 7,27 (dd, J = 12,6, 1,9 Hz, 1H), 7,20 (dd, J = 8,8, 1,6 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,54 (d, J = 4,3 Hz, 1H), 3,88 -3,76 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,48 -3,37 (m, 1H), 1,98 -1,82 (m, 4H), 1,43 -1,20 (m, 4H)
I -70
0,004 527,2 RMN-1H (400 MHz, DMSO) δ 9,41 (d, J = 8,5 Hz, 1H), 9,35 (s, 1H), 7,93 (d, J = 8,5 Hz, 1H), 7,91 (s, 1H), 7,53 (s, 1H), 7,40 (d, J = 10,4 Hz, 1H), 7,33 (s, 1H), 7,28 (dd, J = 12,6, 1,8 Hz, 1H), 7,19 (d, J = 8,6 Hz, 1H), 7,14 (t, J = 8,5 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,88 (d, J = 48,8 Hz, 1H), 4,26 (m, 1H), 4,03 (t, J = 12,4 Hz, 1H), 3,93 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,69 -3,47 (m, 2H), 2,01 (m, 1H), 1,70 (d, J = 9,4 Hz, 1H)
1. Ensayo enzimático de la ERK-2 (Ejemplo 9) 2. APCI-pos m/z (M + 1) 3. m/z (M + 1), (M + 3)
Otros compuestos representativos en el ámbito de la presente invención están recogidos en la TABLA II. Estos ejemplos son ilustrativos y no deben ser interpretados como limitantes del ámbito de la invención, sino simplemente como representativos de la misma. Los compuestos de la TABLA II se preparan mediante el uso de una metodología descrita ampliamente en los Ejemplos que siguen y están completamente posibilitados.
TABLA II
Comp. Nº
Estructura EM CI501 (µM) RMN-1H (400 MHz, DMSO-d6)
II -1
521,1 0,0062 δ 9,44 (d, J = 8,4 Hz, 1H), 9,41 (s, 1H), 8,39 (s, 1H), 7,98 (s, 1H), 7,54 (s, 1H), 7,45 (d, J = 10,3 Hz, 1H), 7,32 (s, 1H), 7,28 (dd, J = 12,6, 1,8 Hz, 1H), 7,22 -7,17 (m, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 5,07 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 1,40 (d, J = 7,0 Hz, 3H)
II -2
521,1 0,0136 δ 9,44 (d, J = 8,5 Hz, 1H), 9,41 (s, 1H), 8,40 (s, 1H), 7,96 (s, 1H), 7,54 (s, 1H), 7,45 (d, J = 10,4 Hz, 1H), 7,33 (s, 1H), 7,27 (dd, J = 12,6, 1,8 Hz, 1H), 7,20 (d, J = 8,6 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,24 (d, J = 8,4 Hz, 1H), 5,07 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 1,40 (d, J = 7,0 Hz, 3H)
II -3
511,1 0,0528 δ 9,40 (d, J = 8,5 Hz, 1H), 9,28 (s, 1H), 8,30 (s, 1H), 8,07 (s, 1H), 7,94 (d, J = 8,3 Hz, 1H), 7,72 (dd, J = 8,3, 1,3 Hz, 1H), 7,54 (s, 1H), 7,37 -7,24 (m, 2H), 7,17 (dt, J = 17,2, 8,6 Hz, 2H), 6,27 (d, J = 8,5 Hz, 1H), 4,61 (d, J = 9,3 Hz, 3H), 4,27 (dd, J = 9,7, 6,8 Hz, 2H), 3,82 (s, 3H), 3,79 (s, 3H)
II -4
509,2 0,0157
II -5
479,1 0,013 δ 9,37 (d, J = 8,6 Hz, 1H), 9,22 (s, 1H), 8,23 (d, J = 7,3 Hz, 1H), 8,05 (s, 1H), 7,88 (d, J = 8,3 Hz, 1H), 7,67 (dd, J = 8,3, 1,4 Hz, 1H), 7,55 (s, 1H), 7,35 -7,25 (m, 2H), 7,23 -7,18 (m, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,26 (d, J = 8,5 Hz, 1H), 5,34 (dd, J = 16,8, 8,4 Hz, 1H), 3,81 (d, J = 11,9 Hz, 6H), 3,51 (t, J = 9,1 Hz, 2H), 3,35 -3,32 (m, 2H)
II -6
509,2 0,157
II -7
479,1 0,0056 δ 9,41 (d, J = 8,5 Hz, 1H), 9,35 (s, 1H), 8,34 (s, 1H), 7,94 (s, 1H), 7,54 (s, 1H), 7,41 (d, J = 10,5 Hz, 1H), 7,33 (s, 1H), 7,27 (dd, J = 12,6, 1,9 Hz, 1H), 7,22 -7,18 (m, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,32 (s, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,08 -2,95 (m, 2H), 2,81 -2,63 (m, 3H)
II -8
477,1 0,0042 δ 9,34 (d, J = 8,6 Hz, 1H), 9,14 (s, 1H), 7,99 (s, 1H), 7,81 (t, J = 14,2 Hz, 2H), 7,61 (dd, J = 8,3, 1,3 Hz, 1H), 7,54 (s, 1H), 7,38 7,24 (m, 2H), 7,17 (dt, J = 29,9, 8,6 Hz, 2H), 6,26 (d, J = 8,5 Hz, 1H), 5,06 (d, J = 5,7 Hz, 1H), 3,90 (ddd, J = 22,1, 16,0, 7,9 Hz, 2H), 3,81 (d, J = 12,5 Hz, 6H), 2,71 -2,56 (m, 2H), 1,87 (ddd, J = 17,2, 8,6, 2,7 Hz, 2H)
II -9
477,2 0,0038 δ 9,35 (d, J = 8,6 Hz, 1H), 9,15 (s, 1H), 8,01 (s, 1H), 7,84 (d, J = 8,3 Hz, 2H), 7,62 (dd, J = 8,3, 1,3 Hz, 1H), 7,55 (s, 1H), 7,36 7,24 (m, 2H), 7,23 -7,11 (m, 2H), 6:26 (d, J = 8,6 Hz, 1H), 5,00 (d, J = 5,2 Hz, 1H), 4,47 (s, 1H), 4,34 (dd, J = 11,3, 6,0 Hz, 1H), 3,81 (d, J = 12,0 Hz, 6H), 2,32 -2,12 (m, 4H)
II -10
491,2 0,0138 δ 9,35 (d, J = 8,6 Hz, 1H), 9,15 (s, 1H), 7,99 (s, 1H), 7,84 (d, J = 8,3 Hz, 2H), 7,62 (dd, J = 8,3, 1,3 Hz, 1H), 7,54 (s, 1H), 7,37 7,24 (m, 2H), 7,17 (dt, J = 30,0, 8,6 Hz, 2H), 6,26 (d, J = 8,6 Hz, 1H), 4,09 (d, J = 8,0 Hz, 1H), 3,81 (d, J = 12,6 Hz, 6H), 3,64 (p, J = 7,2 Hz, 1H), 3,15 (s, 3H), 2,67 (t, J = 7,9 Hz, 2H), 1,89 (ddd, J = 16,9, 8,8, 2,7 Hz, 2H)
II -11
478,2 0,0139 δ 9,42 (d, J = 8,5 Hz, 1H), 9,35 (s, 1H), 8,15 (s, 1H), 7,95 (s, 1H), 7,54 (s, 1H), 7,42 (d, J = 10,4 Hz, 1H), 7,33 (s, 1H), 7,28 (dd, J = 12,6, 1,9 Hz, 1H), 7,20 (d, J = 8,6 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,2 Hz, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,64 (s a, 2H), 2,88 (m, 2H)
II -12
479,2 0,0012 δ 9,46 (d, J = 8,4 Hz, 1H), 9,30 (s, 1H), 7,92 (s, 1H), 7,84 (s, 1H), 7,56 (s, 1H), 7,44 -7,33 (m, 3H), 7,30 -7,23 (m, 2H), 7,10 (td, J = 8,8, 2,4 Hz, 1H), 6,32 (d, J = 8,3 Hz, 1H), 4,10 (s a, 1H), 3,90 (d, J = 11,1 Hz, 2H), 3,79 (s, 3H), 3,42 (t, J = 11,1 Hz, 2H), 1,89 (d, J = 11,5 Hz, 2H), 1,59 (cd, J = 11,4, 4 Hz, 2H)
II -13
imagen30 523,2 0,0012 δ 9,40 (d, J = 8,0 Hz, 1H), 9,25 (s, 1H), 7,91 (s, 1H), 7,68 (d a, J = 6,8 Hz, 1H), 7,54 (s, 1H), 7,33 (d, J = 9,6 Hz, 1H), 7,32 (s, 1H), 7,27 (dd, J = 12,6, 1,9 Hz, 1H), 7,20 (dd, J = 8,8, 1,6 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 4,54 (d, J = 4,3 Hz, 1H), 3,88 -3,76 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,48 -3,37 (m, 1H), 1,98 -1,82 (m, 4H), 1,43 -1,20 (m, 4H)
II -14
492,2 0,153 δ 9,39 (d, J = 8,2 Hz, 1H), 9,29 (s, 1H), 8,24 (d, J = 2,8 Hz, 1H), 7,92 (s, 1H), 7,83 (s, 1H), 7,55 (s, 1H), 7,45 (d, J = 8,6 Hz, 1H), 7,41 -7,34 (m, 2H), 7,34 (s, 1H), 6,29 (d, J = 8,2 Hz, 1H), 4,08 (m, 1H), 3,90 (m, 2H), 3,82 (s, 3H), 3,78 (s, 3H), 3,42 (t, J = 10,9 Hz, 2H), 1,89 (d, J = 11,7 Hz, 2H), 1,59 (cd, J = 12,0, 4,4 Hz, 2H)
II -15
527,2 0,0043
II -16
487,2 0,0021 δ 9,71 (s, 1H), 9,38 (d, J = 7,5 Hz, 2H), 8,15 (s, 1H), 8,00 (d, J = 8,4 Hz, 1H), 7,80 (d, J = 8,3 Hz, 1H), 7,53 (s, 1H), 7,39 (d, J = 1,7 Hz, 1H), 7,32 (s, 1H), 7,27 (d, J = 12,7 Hz, 1H), 7,16 (dt, J = 17,1,8,5 Hz, 2H), 6,40 (s, 1H), 6,27 (d, J = 8,5 Hz, 1H), 3,82 (s, 3H), 3,79 (d, J = 3,7 Hz, 3H), 3,73 (d, J = 11,7 Hz, 3H)
II -17
498,1 0,0048
II -18
501,2 0,0021 δ 9,64 (s, 1H), 9,38 (d, J = 8,8 Hz, 2H), 8,15 (s, 1H), 7,99 (d, J = 8,4 Hz, 1H), 7,79 (dd, J = 8,3, 1,2 Hz, 1H), 7,54 (s, 1H), 7,32 (s, 1H), 7,29 -7,24 (m, 1H), 7,20 (d, J = 10,2 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,27 (d, J = 8,4 Hz, 1H), 6,18 (s, 1H), 3,80 (d, J = 13,1 Hz, 6H), 3,63 (s, 3H), 2,14 (s, 3H)
II -19
imagen31 519,2 0,0068
II -20
imagen32 523 0,0097 δ 9,39 (d, J = 8,5 Hz, 1H), 9,26 (s, 1H), 7,88 (s, 1H), 7,70 (s, 1H), 7,54 (s, 1H), 7,32 (d, J = 10,4 Hz, 1H), 7,32 (s, 1H), 7,27 (d, J = 12,7 Hz, 1H), 7,19 (d, J = 9,8 Hz, 1H), 7,13 (t, J = 8,6 Hz, 1H), 6,55 (s, 1H), 6,24 (d, J = 8,4 Hz, 1H), 4,35 (d, J = 2,4 Hz, 1H), 3,87 (s, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,76 (s, 1H), 1,86 -1,58 (m, 6H), 1,51 (t, J = 11,9 Hz, 2H)
II -21
483,1 0,0023 δ 9,38 (d, J = 8,4 Hz, 1H), 9,28 (s, 1H), 7,88 (s, 1H), 7,54 (s, 1H), 7,49 (s a, 1H), 7,34 (d, J = 10 Hz, 2H), 7,32 (s, 1H), 7,27 (d, J = 12,5 Hz, 1H), 7,19 (d, J = 9,9 Hz, 1H), 7,13 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,5 Hz, 1H), 4,71 (t, J = 5,6 Hz, 1H), 4,12 (septuplete, J = 7 Hz, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,53 (dt, J = 10,7, 5,4 Hz, 1H), 3,43 -3,35 (dt, J = 10,8, 5,2 Hz, 1H), 1,18 (d, J = 6,6 Hz, 3H)
II -22
491,1 0,0070 δ 9,37 (d, J = 8,5 Hz, 1H), 9,29 (s, 1H), 7,90 (s a, 1H), 7,79 (s a, 1H), 7,51 (s, 1H), 7,38 -7,30 (m, 4H), 6,91 (d, J = 8,7 Hz, 2H), 6,25 (d, J = 8,4 Hz, 1H), 4,07 (s a, 1H), 3,90 (d, J = 11,5 Hz, 1H), 3,79 (s, 3H), 3,74 (s, 3H), 3,42 (t, J = 10,8 Hz, 2H), 1,89 (d, J = 11,6 Hz, 2H), 1,59 (cd, J = 11,7, 4,3 Hz, 2H)
II -23
505,1 0,0108
II -24
505,1 0,0146 δ 9,62 (s, 1H), 9,43 (d, J = 8,3 Hz, 1H), 9,37 (s, 1H), 8,16 (s, 1H), 8,00 (d, J = 8,4 Hz, 1H), 7,79 (dd, J = 8,4, 1,6 Hz, 1H), 7,57 (t, J = 8,0 Hz, 2H), 7,47 (dd, J = 10,6, 2,0 Hz, 1H), 7,36 (s, 1H), 7,31 (dd, J = 8,3, 1,9 Hz, 1H), 6,33 (d, J = 8,3 Hz, 1H), 6,18 (s, 1H), 3,79 (s, 3H), 3,63 (s,3H), 2,14 (s, 3H)
II -25
491,0 0,0031 δ 9,69 (s, 1H), 9,43 (d, J = 8,3 Hz, 1H), 9,39 (s, 1H), 8,16 (s, 1H), 8,01 (d, J = 8,4 Hz, 1H), 7,80 (dd, J = 8,4, 1,5 Hz, 1H), 7,57 (t, J = 8,1 Hz, 2H), 7,47 (dd, J = 10,5, 2,0 Hz, 1H), 7,38 (d, J = 1,9 Hz, 1H), 7,36 (s, 1H), 7,31 (dd, J = 8,4, 1,9 Hz, 1H), 6,39 (d, J = 1,9 Hz, 1H), 6,32 (d, J = 8,3 Hz, 1H), 3,79 (s, 3H), 3,72 (s, 3H)
II -26
453,0 0,0056 δ 9,43 (d, J = 8,4 Hz, 1H), 9,28 (s, 1H), 7,89 (s, 1H), 7,57 (s, 1H), 7,46 (s, 1H), 7,40 (td, J = 8,2, 6,2 Hz, 1H), 7,3 5 (dd, J = 10,6, 1,0 Hz, 1H), 7,35 (s, 1H), 7,28 (d, J = 7,6 Hz, 1H), 7,26 (d, J = 10,8 Hz, 1H), 7,09 (td, J = 8,6,2,4 Hz, 1H), 6,32 (d, J = 8,4 Hz, 1H), 4,69 (t, J = 5,6 Hz, 1H), 4,19 -4,07 (m, 1H), 3,79 (s, 3H), 3,53 (dt, J = 10,8, 5,5 Hz, 1H), 3,44 -3,36 (m, 1H), 1,19 (d, J = 6,6 Hz, 3H)
II -27
501,2 0,96
II -28
491,2 0,003
II -29
509,2 0,0022
II -30
503,3 1
II -31
imagen33 479,1 0,015 δ 9,34 (d, J = 8,6 Hz, 1H), 9,16 (s, 1H), 8,00 (s, 1H), 7,84 (d, J = 8,3 Hz, 1H), 7,62 (dd, J = 8,3, 1,5 Hz, 1H), 7,54 (s, 1H), 7,39 7,24 (m, 3H), 7,16 (dt, J = 17,2, 8,6 Hz, 2H), 6,26 (d, J = 8,5 Hz, 1H), 4,37 -4,25 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 3,47 (dd, J = 9,4, 6,0 Hz, 1H), 3,41 -3,33 (m, 1H), 3,28 (s, 3H), 1,18 (d, J = 6,7 Hz, 3H)
II -32
497,2 0,0045 δ 9,40 (d, J = 8,4 Hz, 1H), 9,31 (s, 1H), 8,23 (s, 1H), 7,93 (s, 1H), 7,54 (s, 1H), 7,38 (d, J = 10,4 Hz, 1H), 7,32 (s, 1H), 7,27 (d, J = 12,7 Hz, 1H), 7,20 (d, J = 8,7 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,25 (d, J = 8,4 Hz, 1H), 5,29 (d, J = 56,8 Hz, 1H), 4,67 -4,54 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 2,64 -2,50 (m, 2H), 2,50 -2,38 (m, 2H)
II -33
imagen34 497,1 0,0038 δ 9,39 (d, J = 8,5 Hz, 1H), 9,31 (s, 1H), 8,19 (s, 1H), 7,88 (s, 1H), 7,54 (s, 1H), 7,38 (d, J = 10,4 Hz, 1H), 7,33 (s, 1H), 7,27 (d, J = 12,8 Hz, 1H), 7,19 (d, J = 8,6 Hz, 1H), 7,14 (t, J = 8,6 Hz, 1H), 6,24 (d, J = 8,4 Hz, 1H), 4,91 (d, J = 56,6 Hz, 1H), 4,12 -3,98 (m, 1H), 3,82 (s, 3H), 3,79 (s, 3H), 2,87 -2,75 (s, 2H), 2,34 -2,18 (m, 2H)
II -34
521,2 1
II -35
492,1 0,061 δ 9,39 (d, J = 8,3 Hz, 1H), 9,30 (s, 1H), 8,35 (d, J = 5,7 Hz, 1H), 7,93 (s, 1H), 7,84 (s, 1H), 7,58 (s, 1H), 7,39 -7,33 (m, 2H), 7,11 (d, J = 2,3 Hz, 1H), 6,89 (dd, J = 5,7, 2,4 Hz, 1H), 6,27 (d, J = 8,3 Hz, 1H), 4,10 (s, 1H), 3,90 (d, J = 11,3 Hz, 2H), 3,82 (s, 3H), 3,78 (s, 3H), 3,42 (t, J = 11,3 Hz, 2H), 1,89 (d, J = 12,1 Hz, 2H), 1,59 (m, 2H)
(500 MHz, CDCl3): δ9,15 (s, 1H),
7,99 (s, 1H), 7,89 (d, J = 8,0 Hz,
1H), 7,66 (d, J = 8,5 Hz, 1H),
7,44 (s, 1H), 7,19 -7,14 (m, 3H),
II -36
509,2 0,0038 6,55 (s, 1H), 6,13 (s, 1H), 4,80 (s, 1H), 4,45 -4,37 (m, 1H), 4,18
4,04 (m, 2H), 3,90 (s, 3H), 3,82
(s, 3H), 3,78 -3,60 (m, 2H), 2,14
-2,04 (m, 1H), 1,89 -1,87 (m,
1H)
II -37
509,2 0,0036 (500 MHz, DMSO-d6): δ 9,64 (d, J = 8,0 Hz, 1H), 9,22 (s, 1H), 8,07 (s, 1H), 7,90 -7,84 (m, 2H), 7,67 (d, J = 8,0 Hz, 1H), 7,35 7,33 (m, 2H), 7,26 -7,17 (m, 2H), 6,49 (d, J = 8,0 Hz, 1H), 5,95 (s, 1H), 4,65 (s, 0,5H), 4,55 (s, 0,5H), 4,38 (s, 1H), 4,06 -4,02 (m, 1H), 3,86 -3,83 (m, 1H), 3,80 (s, 3H), 3,74 (s, 3H), 3,51 -3,42 (m, 2H), 2,08 -2,01 (m, 1H), 1,68 -1,61 (m, 1H)
II -38
487,3 0,0029 (500 MHz, DMSO-d6): δ 9,70 (s, 1H), 9,63(d, J = 8,5 Hz, 1H), 9,39 (s, 1H), 8,16 (s, 1H), 8,01 (d, J = 8,0 Hz, 1H), 7,80 (d, J = 8,5 Hz, 1H), 7,38 (d, J = 1,5, 1H) 7,34 7,30 (m, 2H), 7,26 -7,16 (m, 2H), 6,49 (d, J = 8,5 Hz, 1H), 6,39 (d, J = 1,5 Hz, 1H), 5,93 (d, J = 2,0 Hz, 1H), 3,83 (s, 3H), 3,73 (s, 3H), 3,71 (s, 3H)
II -39
495,3 0,151 (500 MHz, DMSO-d6): δ 9,68 (d, J = 8,0 Hz, 1H), 9,17 (s, 1H), 8,06 (s, 1H), 7,86 (d, J = 8,0 Hz, 1H), 7,65 -7,53 (m, 4H), 7,38 7,33 (m, 2H), 6,57 (d, J = 8,5 Hz, 1H), 5,89 (d, J = 1,5 Hz, 1H), 4,09 -4,05 (m, 1H), 3,89 (d, J = 11,0 Hz, 2H), 3,77 (s, 3H), 3,44 3,38 (m, 2H), 1,89 -1,86 (m, 2H), 1,61 -1,53 (m, 2H)
II -40
imagen35 502,1 0,026 (500 MHz, DMSO-d6): δ 9,73 (d, J = 8,0 Hz, 1H), 9,18 (s, 1H), 8,08 -8,02 (m, 2H), 7,88 -7,86 (m, 2H), 7,69 -7,60 (m, 3H), 7,34 (d, J = 1,5 Hz, 1H), 6,65 (d, J = 8,0 Hz, 1H), 5,85 (d, J = 2,0 Hz, 1H), 4,07 (s, 1H), 3,89 (d, J = 11,5 Hz, 2H), 3,80 (s, 3H), 3,44 3,41 (m, 2H), 1,91 -1,87 (m, 2H), 1,60 -1,53 (m, 2H)
II -41
529,3 0,0052
II -42
498,1 0,0346
II -43
509,3 0,0121
II -44
imagen36 548,2 0,216
II -45
550,3 0,0069
II -46
509,2 0,0011
II -47
496,2 0,0013
II -48
510,2 0,0014
II -49
509,3 0,0855
II -50
imagen37 495,2 0,0591
II -51
imagen38 509,2 0,164
II -52
509,2 0,0019
II -53
505,2 0,0015
II -54
505,2 0,0085
1. Ensayo enzimático de la ERK-2 (Ejemplo 9)
Los compuestos de la presente invención pueden ser elaborados mediante diversos métodos representados en los esquemas de reacción sintéticos ilustrativos mostrados y descritos a continuación. Los materiales y reactivos de partida usados en la preparación de estos compuestos generalmente están disponibles en proveedores comerciales, tales como Sigma Aldrich Chemical Co., o se preparan mediante métodos conocidos por los expertos en la materia. Los procedimientos sintéticos aplicables generalmente descritos en los tratados se establecen en referencias tales como Reagents for Organic Synthesis, de Fieser y Fieser; Wiley & Sons: Nueva York, Volúmenes 1 -21; R. C. LaRock, Comprehensive Organic Transformations, 2ª edición Wiley-VCH, Nueva York 1999; Comprehensive
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES12769775.3T 2011-08-04 2012-08-03 Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina Active ES2552989T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515165P 2011-08-04 2011-08-04
US201161515165P 2011-08-04
PCT/US2012/049551 WO2013020062A1 (en) 2011-08-04 2012-08-03 Quinazoline compounds as serine/threonine kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2552989T3 true ES2552989T3 (es) 2015-12-03

Family

ID=47003195

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12769775.3T Active ES2552989T3 (es) 2011-08-04 2012-08-03 Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina

Country Status (11)

Country Link
US (1) US9187462B2 (es)
EP (1) EP2739618B1 (es)
JP (1) JP6097289B2 (es)
KR (1) KR101979042B1 (es)
CN (1) CN103958502B (es)
BR (1) BR112014002675A2 (es)
CA (1) CA2844058A1 (es)
ES (1) ES2552989T3 (es)
MX (1) MX340756B (es)
RU (1) RU2014108140A (es)
WO (1) WO2013020062A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
CA2882750A1 (en) * 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
EP2909206A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
CN103254142B (zh) * 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
MX375902B (es) 2013-12-30 2025-03-07 Genentech Inc Inhibidores de serina/treonina cinasa.
KR102379517B1 (ko) * 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
SG11202013175SA (en) 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN115243687A (zh) 2019-10-25 2022-10-25 默沙东有限责任公司 作为lrrk2抑制剂的n-(杂芳基)喹唑啉-2-胺衍生物、药物组合物及其用途
CN115448864B (zh) * 2022-08-26 2023-12-22 上海方予健康医药科技有限公司 3-氟-3-（1-羟乙基）吡咯烷-1-羧酸叔丁酯的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2274093C (en) 1996-12-05 2006-11-07 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
YU63802A (sh) 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
AU2001252606B2 (en) 2000-04-26 2005-07-07 Eisai R&D Management Co., Ltd. Medicinal compositions promoting bowel movement
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
MXPA04011470A (es) 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
WO2004007468A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
JP2007532669A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2578122A1 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
CA2661334C (en) 2006-08-23 2011-11-29 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
MX2010005033A (es) 2007-11-06 2010-05-27 Du Pont Aminas heterociclicas fungicidas.
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases

Also Published As

Publication number Publication date
EP2739618B1 (en) 2015-09-16
KR101979042B1 (ko) 2019-05-15
HK1199248A1 (zh) 2015-06-26
US9187462B2 (en) 2015-11-17
JP2014521696A (ja) 2014-08-28
CN103958502A (zh) 2014-07-30
JP6097289B2 (ja) 2017-03-15
WO2013020062A1 (en) 2013-02-07
RU2014108140A (ru) 2015-09-10
US20150087664A1 (en) 2015-03-26
EP2739618A1 (en) 2014-06-11
HK1199021A1 (zh) 2015-06-19
BR112014002675A2 (pt) 2017-02-21
MX340756B (es) 2016-07-25
MX2014001389A (es) 2014-11-13
KR20140062057A (ko) 2014-05-22
CN103958502B (zh) 2016-02-10
CA2844058A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
IL275649B2 (en) Irak degraders and uses thereof
KR20240163107A (ko) 헤테로환 화합물 및 이의 용도
US20090048429A1 (en) Processes and intermediates
EP4638457A1 (en) Heterocycles and uses thereof
JP6378182B2 (ja) 過剰増殖性│疾患の処置のためのセリン／スレオニンキナーゼ阻害剤
JP2021020924A5 (es)
UA117666C2 (uk) 2-заміщені сполуки цефему
JP2024529126A (ja) 細胞傷害性標的キメラ
AU2020405536B2 (en) Benzimidazole derivatives
BR112016004593B1 (pt) Métodos para reagir um composto, para hidrolisar um composto ou um sal do mesmo, para produzir um composto e para preparar um composto
WO2022100688A1 (zh) Hpk1激酶调节剂、其制备方法与应用
CN116783184A (zh) 含有烷基-氧杂环烷基部分的氨磺酰基脲衍生物及其用途
TW202440578A (zh) ２，６，９－三取代嘌呤
AU2023229518A1 (en) C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof
ZA200607634B (en) Caspase inhibitors and uses thereof
CN113891882B (zh) 二氢异噁唑的制造方法
IL283194B1 (en) Macrolides with 13 members converted to C10-alkylene and their uses
JP2024509437A (ja) 新規ベンズアゼピン縮合環式誘導体
WO2025237323A1 (zh) 噻唑类sting抑制剂及其医药用途
KR102877899B1 (ko) Hiv 억제제로서의 신규한 트리테르펜 유도체
CN114956929A (zh) 一种手性腈类化合物的合成方法
Hovey Jr Development and Application of Carbene Catalysis for Synthesis
TW202440076A (zh) 阿維菌素衍生物
WO2025247394A1 (zh) 含氮杂环化合物、其药物组合物及应用
El Hilali Part I: Studies toward the Total Synthesis of Myriaporone 3/4. Part II:(Diisopinocampheyl) borane-Mediated Reductive Aldol Reactions of Allenyl Carboxamides